Menu
Fechar
hrs4r
 I want to donate

The Research Group in Radiation Oncology and Medical Physics of Girona (ONCORFIM Girona) is a multidisciplinary group whose mission is to improve oncological outcomes and quality of life of our patients by applying new technologies.

The way to achieve this goal, will be from the following key points for us.

  1. Minimize the dose received in critical organs and improve clinical outcomes.
  2. Predict response and toxicity to radiotherapy treatment.
  3. Use new digital technologies to achieve the previously described (ICOnnecta't).
Main lines of research

Line 1: Prevention of cardiotoxicity and radiotherapy in breast cancer.

Prevention of cardiotoxicity in breast cancer patients undergoing cardiotoxic treatments such as radiotherapy (Arantxa Eraso).

Cardiotoxicity in external radiotherapy: clinical impact of the dose delivered (Ingrid Romera).

The following projects are underway within this line:

  • Horizon 2020 Project Medirad. Early detection of cardiovascular changes after radiotherapy in breast cancer. Reference: EARLY-HEART. Principal Investigator: Arantxa Eraso.
  • Development and clinical implementation of the DIFGI device in forced inspiration techniques maintained in left breast cancer treatments with external radiotherapy to reduce the dose to the heart. Doctoral candidate: Ingrid Romera. Thesis supervisors: Joan Carles Vilanova and Rafael Fuentes.
  • Impact of a structured physical exercise program and control of cardiovascular risk factors in the primary prevention of cardiotoxicity in breast cancer patients undergoing cardiotoxic treatments: Estudi PREV (Arantxa Eraso).

Line 2: Technological advances in radiotherapy (ablative radiotherapy, intraoperative radiotherapy techniques, new techniques and quality in radiotherapy).

  • Use of Intraoperative Radiotherapy in breast neoplasia. Reference: RIOMA. Principal Investigator: Arantxa Eraso.
  • Phase II trial of Electronic Brachytherapy in the post-surgical treatment of endometrial cancer (Hugo Rosales and Ester Oliva).
  • Ablative radiotherapy in different locations, the most innovative being the Pancreatic SBRT (Eugeni Canals).
  • Dose determination, technology and quality in external radiotherapy (Diego Jurado Bruggeman).
  • Clinical impact of dose calculation in external radiotherapy and associated technological and quality assurance aspects (Carles Muñoz Montplet).

Line 3: Biomarkers of response to radiotherapy.

  • BIOMARKERS AS PREDICTORS OF RESPONSE IN RECTAL CANCER.
  • Radiogenomics: identification of biomarkers by genome-wide association studies (GWAS) and exome sequencing (WES) in extreme phenotypes.
  • Radiosensitivity studies in cancer patients at high risk of toxicity. Reference: PRED-RAD. Collaborating researchers: Arantxa Eraso, Rafael Fuentes and Àlvar Roselló.

Line 4: e-Health and humanization in the Radiation Oncology process.

  • Online screening and monitoring of symptomatology secondary to Radiation therapy treatment of digestive tumors: a prospective controlled clinical trial.
  • Prostate Cancer Outcomes Global initiative to compare and reduce variation in localized prostate cancer. Reference: PCO-CRV. Principal Investigator: Àlvar Roselló.

IROCATES: Quality improvement in Radiation Oncology through Clinical Audits. Principal Investigators: Carles Muñoz and Àlvar Roselló.

Strategic objectives

The objective of the group is to conduct research in the hospital setting in an area in which technological advances are oriented towards the modification of clinical practice towards personalized and precision medicine: Treatment for the right patient vs. treatment for a disease.

Publications
Marruecos Querol J, Jurado-Bruggeman D, Lopez-Vidal A, Mesía Nin R, Rubió-Casadevall J, Buxó M, Eraso Urien A

Contouring aid tools in radiotherapy. Smoothing: the false friend

CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26, 1956-1967 dx.doi.org/10.1007/s12094-024-03420-9
Zamora, V, Garin, O, Suárez, JF, Gutiérrez, C, Guedea, F, Cabrera, P, Castells, M, Herruzo, I, Fumadó, L, Samper, P, Ferrer, C, Regis, L, Pont, A, Ferrer, M

Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures

Clinical and Translational Radiation Oncology, 2024, 44 dx.doi.org/10.1016/j.ctro.2023.100694
Barclay NL, Burkard T, Burn E, Delmestri A, Miquel Dominguez A, Golozar A, Guarner-Argente C, Avilés-Jurado FX, Man WY, Roselló Serrano À, Rosen AW, Tan EH, Tietzova I, Prieto Alhambra D, Newby D

The Impact of the COVID-19 Pandemic on Incidence and Short-Term Survival for Common Solid Tumours in the United Kingdom: A Cohort Analysis

Clinical Epidemiology, 2024, 16, 417-429 dx.doi.org/10.2147/CLEP.S463160
Barclay NL, Català M, Jödicke AM, Prieto-Alhambra D, Newby D, Delmestri A, Man WY, Serrano ÀR, Moncusí MP

Collateral effects of the COVID-19 pandemic on endocrine treatments for breast and prostate cancer in the UK: a cohort study

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16 dx.doi.org/10.1177/17588359241253115
Carver, A, Scaggion, A, Jurado-Bruggeman, D, Blanck, O, Dalqvist, E, Giglioli, FR, Jenko, A, Karlsson, K, Staykova, V, Swinnnen, A, Warren, S, Mancosu, P, Jornet, N

Treatment planning and delivery practice of lung SBRT: Results of the 2022 ESTRO physics survey

RADIOTHERAPY AND ONCOLOGY, 2024, 196 dx.doi.org/10.1016/j.radonc.2024.110318
Tan EH, Burn E, Barclay NL, Delmestri A, Man WY, Golozar A, Serrano ÀR, Duarte-Salles T, Cornford P, Prieto Alhambra D, Newby D

Incidence, Prevalence, and Survival of Prostate Cancer in the UK.

JAMA Network Open, 2024, 7 dx.doi.org/10.1001/jamanetworkopen.2024.34622
Bonet M, González D, Baquedano JE, García E, Altabas M, Casas F, Feltes N, Ferrer F, Foro P, Fuentes R, Galdeano M, Gomez D, Henriquez I, Jové J, Lozano J, Maldonado X, Mases J, Membrive I, Paredes S, Roselló À, Sancho G, Mira M

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 1017-1023 dx.doi.org/10.1007/s12094-022-03005-4
Marruecos-Querol J, Rubió-Casadevall J, Lozano A, Buxó M, Puigdemont M, Linares I, Planas I, Vayreda J, Cirauqui B, Taberna M, Quiroga V, Tobed M, Borés A, Recalde S, Saigi M, Felip E, Eraso A, Mesía R

Validation of a prognostic model for predicting larynx preservation outcome (TALK score) in a Southern European population

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 2384-2392 dx.doi.org/10.1007/s12094-023-03121-9
Auñón C, Sanvisens A, Turon E, Vidal-Vila A, Puigdemont M, Osca-Gelis G, Eraso A, Marcos-Gragera R

Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018)

CANCER MEDICINE, 2023, 12, 12343-12353 dx.doi.org/10.1002/cam4.5935
Pardo García R, Piñero Madrona A, Algara López M, Bernet Vegué L, Eraso Urien A

Just medical oncology guidelines...

CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25, 3319-3320 dx.doi.org/10.1007/s12094-023-03272-9
Competitive projects
Radiation Oncology and Medical Physics of Girona

Linfadenectomía axilar versus radioterapia axilar en pacientes con ganglio centinela positivo tras terapia neodyuvante. Estudio multicéntrico randomizado fase III.

Codi oficial: ADARNAT I Start date:09/12/2022 Data fi: 09/12/2027 Investigador/a principal: LUIS MIGUEL ALONSO RUANO, ARANTXA ERASO URIÉN Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER
Radiation Oncology and Medical Physics of Girona

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Oncologia radioteràpica i Física Mèdica de Girona (ONCORFIM Girona)

Codi oficial: 2021 SGR 01463 - ONCORFIM Girona Start date:01/01/2022 Data fi: 30/06/2025 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: AGÈNCIA DE GESTIÓ UNIVERSITARIS I RECERCA
Radiation Oncology and Medical Physics of Girona

Preparatory activities to support Implementation of quality and Safety of Medical ionising radiation Applications

Codi oficial: 101162826 Start date:01/05/2024 Data fi: 31/10/2025 Investigador/a principal: ARANTXA ERASO URIÉN Organisme finançador: EUROPEAN COMISSION
Radiation Oncology and Medical Physics of Girona

Catalan Clinical Audit network for Quality Improvement in RT

Codi oficial: 101161063 Start date:01/10/2024 Data fi: 30/09/2027 Investigador/a principal: CARLES MUÑOZ MONTPLET Organisme finançador: EUROPEAN COMISSION
Transfer
Patents

Carles Muñoz, Ingrid Romera, Diego Jurado, Jordi Marruecos, Salvador Bou, Roger Grèbol.
DEVICE FOR THE POSITIONING OF PATIENTS IN RADIOTHERAPY TREATMENTS
Número de publicació: ES1165083
Data de publicació: 2016-09-21

Job offers

Team

If you are a researcher and you are interested in collaborating with any of our research groups, please fill in this form.
I am interested in
If you are a student or you want to do an internship with any of our research groups, please fill in this form.
I am interested in

About IDIBGI!

 menu